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Abstract 29 
The physiological roles of the factor H-related proteins are controversial and poorly 30 
understood. Based on genetic studies, factor H-related protein 5 (CFHR5) is implicated in 31 
glomerular diseases, such as atypical hemolytic uremic syndrome, dense deposit disease and 32 
CFHR5 nephropathy. CFHR5 was also identified in glomerular immune deposits at the 33 
protein level. For CFHR5, weak complement regulatory activity and competition for C3b 34 
binding with the plasma complement inhibitor factor H have been reported, but its function 35 
remains elusive. Here, we identify pentraxin 3 (PTX3) as a novel ligand of CFHR5. Binding 36 
of native CFHR5 to PTX3 was detected in human plasma and the interaction was 37 
characterized using recombinant proteins. The binding of PTX3 to CFHR5 is of 38 
approximately twofold higher affinity compared to that of factor H. CFHR5 dose-dependently 39 
inhibited factor H binding to PTX3 and also to the monomeric, denatured form of the short 40 
pentraxin C-reactive protein. Binding of PTX3 to CFHR5 resulted in increased C1q binding. 41 
In addition, CFHR5 bound to extracellular matrix in vitro in a dose-dependent manner and 42 
competed with factor H for binding. Altogether, CFHR5 reduced factor H binding and its 43 
cofactor activity on pentraxins and the extracellular matrix, while at the same time allowed for 44 
enhanced C1q binding. Furthermore, CFHR5 allowed formation of the alternative pathway C3 45 
convertase and supported complement activation. Thus, CFHR5 may locally enhance 46 
complement activation via interference with the complement inhibiting function of factor H, 47 
by enhancement of C1q binding and by activating complement, thereby contributing to 48 
glomerular disease. 49 
50 
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Introduction 51 
The human complement factor H-related protein 5 (CFHR5) belongs to the factor H (FH) 52 
protein family (1). This protein family includes two splice variants of the factor H gene, FH 53 
and FH-like protein 1 (FHL-1), and five CFHR proteins (2). All members of this protein 54 
family consist of complement control protein (CCP) domains (also known as sushi domains 55 
or short consensus repeats) and show high degree of sequence similarity to each other and to 56 
FH. Whereas FH is a well-characterized inhibitor of the alternative complement pathway, the 57 
function of the CFHR proteins is controversial (2, 3). In general, the CFHR proteins lack 58 
domains and activity related to the complement regulatory CCP1-4 domains of FH. The C-59 
terminal region is highly conserved within the family: all CFHR proteins possess domains 60 
similar to CCPs 19-20 of FH. Some CFHR proteins, e.g. CFHR3 contain domains with high 61 
similarity to CCP domains 6 and 7 of FH (2). 62 
CFHR5 is a 65-kDa plasma glycoprotein produced in the liver, with a reported serum 63 
concentration of ~3-6 µg/ml (4). CFHR5 consists of 9 CCP domains that are related to CCPs 64 
6-7, CCPs 10-14 and CCPs 19-20 of FH (Figure 1A). CFHR5 was originally isolated from 65 
human glomerular complement deposits (1) with an antibody generated against preparations 66 
of a human kidney with membranoproliferative glomerulonephritis (MPGN) (5). Using this 67 
antibody, CFHR5 was detected in glomerular immune deposits in several kidney diseases, e.g. 68 
membranous nephropathy, IgA nephropathy, lupus nephritis, focal glomerular sclerosis, and 69 
post-infectious glomerulonephritis (6). Variations in the CFHR5 gene were also found in 70 
patients with atypical hemolytic syndrome (aHUS) and MPGN II/dense deposit disease (7-9). 71 
Recently, a subtype of C3 glomerulonephritis was linked to a mutation and internal 72 
duplication in the CFHR5 gene and this disease entity was termed CFHR5 nephropathy (10). 73 
The function of the CFHR5 protein is not well understood. It was reported that CFHR5 has 74 
cofactor activity for factor I in the C3b cleavage and CFHR5 accelerates the decay of the 75 
fluid-phase C3bBb convertase. However, these activities were only evident at non-76 
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physiological concentrations (4). Analyses of the structural properties of CFHR1, CFHR2 and 77 
CFHR5 revealed that these CFHRs form homo- and heterodimers in serum and can deregulate 78 
complement by competing with FH for binding to C3b and surface polyanions (11, 12). 79 
Recently, a hybrid CFHR2-CFHR5 protein was shown to cause deregulation of complement 80 
(13). CFHR5 was also shown to bind to C-reactive protein (CRP), an acute phase protein 81 
belonging to the family of pentraxins (4).  82 
Pentraxins are pattern recognition molecules of the innate immune system and have 83 
the capacity to activate complement by binding C1q (14). CRP can interact with several 84 
members of the factor H protein family, namely FH, FHL-1, CFHR4 and CFHR5 (4, 15, 16), 85 
but the interaction of FH with the denatured monomeric CRP versus native pentameric CRP is 86 
still a controversial issue (16-20). The long pentraxin PTX3 is produced locally by 87 
neutrophils, macrophages, myeloid dendritic cells, fibroblasts, endothelial cells and retinal 88 
pigment epithelial cells under inflammatory conditions (21, 22). Its plasma level is ~2 ng/ml, 89 
which can increase to ~1.5 µg/ml during sepsis, inflammation and infections (23). PTX3 is a 90 
45-kDa glycoprotein and forms stable octamers with disulfide bonds (24). It recruits the 91 
complement regulators FH, FHL-1, CFHR1 and C4b binding protein (25-27). Both CRP and 92 
PTX3 can initiate complement activation and, by binding complement regulators, govern the 93 
reaction to opsonization rather than to the lytic terminal pathway (28). A recent report 94 
described PTX3 complexes that also contain CFHR5 in sepsis serum/plasma samples (29). 95 
The aim of this study was to characterize CFHR5–pentraxin interactions, as well as 96 
interaction with the extracellular matrix that could be exposed during kidney endothelial 97 
injury, and investigate how they influence the regulatory role of FH and activation of 98 
complement. 99 
100 
6 
 
Materials and Methods 101 
 102 
Proteins, antibodies and sera 103 
Recombinant human FHL-1, CFHR1, CCPs 8-14 of FH (FH8-14), CFHR4A and CFHR4B 104 
were generated using the pBSV-8His Baculovirus expression vector (30), expressed in 105 
Spodoptera frugiperda (Sf9) cells, and purified by nickel-affinity chromatography as 106 
described (31, 32). Recombinant human CFHR5, PTX3, anti-CFHR5 monoclonal and 107 
polyclonal antibodies and biotinylated goat anti-human PTX3 antibody were obtained from 108 
R&D Systems (Wiesbaden, Germany). Recombinant mutant CFHR5 with CCPs 1-2 109 
duplicated was produced as described (11). The N- and C-terminal fragments of PTX3 were 110 
obtained as previously described (29). The C-terminal fragments of the CFHR proteins were 111 
generated as described (11). 112 
Purified human FH, C3, C3b, factor B (FB), factor D, properdin (factor P; FP) factor I 113 
(FI), C1q, recombinant human CRP, goat anti-human FH antibody, goat anti-human FB 114 
antibody and goat anti-human C1q antibody were obtained from Merck Ltd. (Budapest, 115 
Hungary). The anti-FH mAb antibody A254 and the anti-FP mAb A235 were from Quidel 116 
(Biomedica, Budapest, Hungary). MaxGel, the goat anti-CRP antibody and the anti-mCRP 117 
mAb (clone CRP-8) were from Sigma-Aldrich Ltd. (Budapest, Hungary). The anti-pCRP 118 
mAb was purchased from Antibodies-online GmbH (Aachen, Germany). Horseradish 119 
peroxidase (HRP)-conjugated goat anti-human C3 was from MP Biomedicals (Solon, OH). 120 
HRP-conjugated swine anti-rabbit immunoglobulins, rabbit anti-goat immunoglobulins and 121 
goat anti-mouse immunoglobulins were from Dako (Hamburg, Germany). 122 
Normal human plasma was collected from healthy individuals after informed consent 123 
and pooled. 124 
 125 
Microtiter plate binding assays 126 
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To analyze binding of native CFHR5 from human plasma to PTX3, 25% normal human 127 
plasma (NHP), diluted in TBS (10 mM Tris, 140 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 128 
pH 7.4), was added for 1 h at 37°C to wells coated with 5 µg/ml PTX3 or gelatin. After 129 
washing, bound proteins were eluted from the wells with SDS sample buffer (60 mM Tris 130 
base, 1% SDS, 10% glycerol, bromophenol blue). Eluted proteins were separated on a 10% 131 
SDS-PAGE gel and analyzed by Western blot using CFHR5-specific antibody. Binding of 132 
CFHR5 and FH to PTX3- and gelatin-coated wells was measured by ELISA using FH 133 
antibody and HRP-conjugated anti-goat Ig. TMB PLUS substrate (Kem-En-Tec Diagnostics, 134 
Denmark) was used to visualize binding and the absorbance was measured at 450 nm. 135 
 To compare PTX3 binding by FH family proteins, Costar microtiter plates (Corning, 136 
NY, USA) were coated with 200 nM each of purified FH, recombinant CFHR1, CFHR4A and 137 
CFHR5, diluted in TBS in 25 µl, overnight at 4°C. The wells were washed after each step 138 
with TBS containing 0.05% Tween-20. After blocking with 4% dry milk in TBS for 2 h at 139 
37°C, 5 µg/ml PTX3 was added in TBS for 1 h at 37°C. Bound PTX3 was detected with a 140 
biotinylated anti-PTX3 Ab followed by HRP-conjugated streptavidin. Calcium- and pH-141 
dependence of PTX3 binding was analyzed as described previously (27). 142 
 To measure PTX3 binding to CFHR protein fragments, wells were coated with 5 143 
µg/ml proteins, followed by blocking with 3% BSA in TBS and incubation with 10 µg/ml 144 
PTX3. PTX3 binding was detected as described above. 145 
 To compare binding of PTX3 and C3b to the mutant and wild-type CFHR5, the 146 
recombinant proteins were immobilized at 10 µg/ml concentration. Binding of 10 µg/ml 147 
PTX3 and 10 µg/ml C3b was measured using the corresponding antibodies. To compare 148 
binding of wild-type and mutant CFHR5 from serum, normal serum and patient serum (11) 149 
diluted 1:1 in TBS were applied to wells coated with 10 µg/ml PTX3 and CRP for 30 min at 150 
37°C. After washing, the eluted proteins were analyzed by Western blot using polyclonal 151 
CFHR5 antibody as described above. 152 
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 Binding of C1q to PTX3 was measured by incubating 10 µg/ml C1q added together 153 
with increasing amounts of CFHR5 and FH to wells coated with 5 µg/ml PTX3 for 1 h at 154 
22°C. C1q binding was detected using anti-C1q. To measure C1q binding to CFHR5-bound 155 
PTX3, microplate wells were coated with 5 µg/ml recombinant CFHR5, with PTX3 and, as 156 
control, with gelatin, and then incubated with 5 µg/ml PTX3 followed by 25 µg/ml or 50 157 
µg/ml C1q. C1q binding was measured using anti-C1q. 158 
For inhibition assays, wells coated with MaxGel (diluted 1:30 in TBS containing Ca2+ 159 
and Mg2+), PTX3 (30 nM) or CRP (87 nM), were incubated with 50 µg/ml FH in the absence 160 
or presence of increasing concentrations of CFHR5 for 1 h at 22°C. FH binding was detected 161 
with the mAb A254, which does not recognize CFHR5. To detect competition between 162 
CFHR5 and FH in serum, heat inactivated (56°C, 30 minutes) human serum was used. Wells 163 
were coated with 10 µg/ml PTX3, 10 µg/ml CRP and MaxGel diluted 1:30 in DPBS. After 164 
blocking with 4% BSA in DPBS, the wells were incubated for 30 minutes at 37°C with 25% 165 
heat inactivated human serum with or without 0.5 µM CFHR5 and CFHR4A. FH binding was 166 
detected with mAb A254 and the corresponding secondary antibody. 167 
Interaction of CFHR5 with pCRP was measured in TBS containing Ca2+ and Mg2+ and 168 
with mCRP, which was generated from commercially available CRP as described (33), in 169 
DPBS (Lonza, Cologne, Germany). CFHR5 and control proteins were immobilized at 5 µg/ml 170 
in microplate wells and, after blocking with 3% BSA in the corresponding buffer, incubated 171 
with up to 50 µg/ml pCRP or mCRP. CRP binding was detected with the goat anti-human 172 
CRP antibody that recognizes both CRP forms (16). In separate assays, CRP was immobilized 173 
in microplate wells at 5 µg/ml in DPBS. Under this condition most bound CRP decays into 174 
the mCRP form (16). After blocking, 300 nM of CFHR5 (20 µg/ml) and FH (50 µg/ml) were 175 
added for 1 h at 22°C and binding was detected using the FH antibody. 176 
 177 
Cofactor assay for C3b inactivation 178 
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To assay FH cofactor activity on surfaces, wells coated with MaxGel (diluted 1:30 in TBS 179 
containing Ca2+ and Mg2+), gelatin (10 µg/ml), PTX3 (30 nM) or CRP (87 nM), were 180 
preincubated with 20 µg/ml CFHR5 for 1 h at 22°C. After washing, 50 µg/ml FH was added 181 
for 1 h at 22°C, followed by thorough washing. Next, 140 nM C3b and 220 nM factor I, 182 
diluted in TBS, were added in 50 µl to the wells, and incubated for 1 h at 37°C. The reactions 183 
were stopped by adding reducing SDS-sample buffer. Samples were then loaded onto 10% 184 
SDS-PAGE gels, separated by electrophoresis and subjected to Western blot. C3 fragments 185 
were detected using HRP-conjugated goat anti-human C3 and an enhanced 186 
chemiluminescence detection kit (Merck). 187 
 188 
Extracellular matrix (ECM) assays 189 
To study the binding of CFHR5, PTX3 and FH to human ECM, MaxGelTM diluted 1:50 in 190 
TBS was immobilized on microtiter plate wells overnight at 4°C and used for subsequent 191 
binding assays (as described above). Endothelial cell-derived ECM was prepared as described 192 
(25, 27) by culturing HUVEC (ATCC; LGC Promochem, Wesel, Germany) on gelatin-coated 193 
96-well tissue culture plates (0.2% gelatin) in DMEM (Lonza) supplemented with 10% FCS, 194 
1% L-glutamine and 50 µg/ml gentamicin sulfate in a cell incubator with humidified 195 
atmosphere containing 5% CO2 for 7 days at 37°C. Cells were washed and detached from the 196 
plate by incubation in DPBS containing 10 mM EDTA at 37°C. Removal of the cells was 197 
monitored by microscopy. The cell-free ECM was washed with TBS and used immediately 198 
for binding assays as described above. The production of ECM by endothelial cells was 199 
confirmed by detecting ECM components after cell detachment, using antibodies against 200 
laminin, collagen type IV, and von Willebrand Factor (Sigma-Aldrich). 201 
 202 
C3 convertase assays 203 
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Formation of the C3bBb alternative pathway C3 convertase on surface-bound CFHR5 and 204 
detection of the C3 convertase components were performed as previously described (34). The 205 
convertase activity was measured by adding 10 µg/ml purified C3 for 1 h at 37°C and 206 
quantifying the generated C3a by a C3a ELISA kit (Quidel). 207 
 208 
Complement activation assays 209 
To measure complement activation due to competition between CFHR5 and FH for ligand 210 
binding, Nunc microplate wells were coated with 10 µg/ml PTX3, 10 µg/ml CRP and MaxGel 211 
diluted 1:30 in DPBS. After blocking with 4% BSA in DPBS, 12.5% normal human serum 212 
(for PTX3 and CRP) and 25% normal human serum (for ECM) were added for 30 minutes at 213 
37°C, with or without 20 µg/ml CFHR5 or CFHR4A. Complement activation was detected by 214 
measuring deposition of C3 fragments using HRP-conjugated goat anti-human C3. 215 
In other experiments, Nunc microtiter plate wells were coated with 5 µg/ml CFHR5, 216 
CFHR4A, FH and HSA, and, after blocking with 3% BSA in DPBS, incubated with 10% 217 
normal human serum with or without 5 mM Mg2+-EGTA or 5 mM EDTA for 30 min at 37°C. 218 
Deposition of C3b, FB and FP was detected using the corresponding primary and secondary 219 
antibodies. 220 
 221 
Statistical analysis 222 
Statistical analysis was performed using GraphPad Prism version 4.00 for Windows 223 
(GraphPad Software, San Diego California USA). A p value < 0.05 was considered 224 
statistically significant. 225 
226 
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Results 227 
 228 
CFHR5 binds to PTX3 229 
Previously, we showed that serum FH and CFHR1 bind to PTX3 (27). To investigate binding 230 
of CFHR5, we incubated human plasma in PTX3-coated wells, and analyzed the bound 231 
proteins after elution and SDS-PAGE by Western blotting using CFHR5-specific antibody. 232 
The native CFHR5 protein was detected by this approach in the PTX3-coated wells but not in 233 
gelatin-coated control wells (Fig. 1B). Direct interaction of CFHR5 with PTX3 was analyzed 234 
by ELISA. Recombinant CFHR5 showed dose-dependent binding to PTX3 and the binding of 235 
CFHR5 to PTX3 reached saturation at a lower concentration compared to the binding of FH 236 
(Fig. 1C). To further analyze this, serial dilutions of PTX3 were applied to CFHR5, 237 
immobilized in microplate wells, and the amount of bound PTX3 was calculated from a 238 
standard curve (Fig. 1D). Dose-dependent binding was observed in the 1-10 nM range; 239 
however, avidity effects complicate affinity determinations because of the octameric nature of 240 
PTX3 and CFHR5 being dimeric, resulting potentially in multivalent binding.  241 
 242 
Characterization of the CFHR5-PTX3 interaction 243 
To compare the binding of PTX3 to CFHR proteins, equimolar amounts of purified FH and 244 
recombinant CFHR1, CFHR4A and CFHR5 were immobilized in microplate wells and PTX3 245 
was added in the fluid phase. CFHR1 showed less PTX3 binding capacity compared to FH, in 246 
agreement with our previous results (27), whereas CFHR5 showed the strongest binding 247 
among the studied proteins (Fig. 2A). PTX3 binding to CFHR4A was rather weak, similar to 248 
that reported previously for CFHR4B (26). 249 
Because the presence of Ca2+ is required for several interactions of pentraxins, the role 250 
of Ca2+ in the binding of PTX3 to CFHR5 was studied. Similar to FH, CFHR5 showed 251 
strongly reduced PTX3 binding when Ca2+ was absent from the buffer (Fig. 2B). 252 
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The binding of PTX3 to FH and FHL-1 was shown to be increased at lower pH (27). 253 
In contrast, we found that the binding of CFHR5 was slightly but significantly reduced at pH 254 
5.5 compared with the physiological pH (Fig. 2C). 255 
 256 
Analysis of binding sites involved in the CFHR5-PTX3 interaction 257 
To determine which domain of PTX3 mediates the binding to CFHR5, recombinant N- and C-258 
terminal PTX3 fragments were immobilized on microtiter plates and incubated with 259 
recombinant CFHR5. CFHR5 bound to both the N- and C-terminal parts of PTX3 (Fig. 3A). 260 
FH also bound to both PTX3 fragments, whereas the control recombinant CCPs 8-14 domains 261 
of FH did not bind to any PTX3 fragment, in agreement with previous results (26). 262 
Because the CCP19-20 domains of FH were shown to be involved in binding PTX3 263 
(26, 27), we investigated the capacity of the homologous CCP8-9 domains of CFHR5, and 264 
also the homologous domains of the other CFHR proteins, to bind PTX3. PTX3 did not bind 265 
to the CFHR5 CCP8-9 fragment, indicating a binding site outside these domains (Fig. 3B). 266 
PTX3 bound to CCP19-20 of FH and CCP4-5 of CFHR1, as expected from previous studies 267 
(26, 27), but it did not bind to CCP3-4 of CFHR2, CCP4-5 of CFHR3 and CCP8-9 of 268 
CFHR4A (Fig. 3B). 269 
A disease-associated CFHR5 protein contains CCPs 1-2 in two copies (Fig. 1A). To 270 
analyze the role of these domains and the capacity of this disease-associated CFHR5 mutant 271 
(mutCFHR5) in PTX3 binding, the binding of PTX3 to immobilized recombinant mutCFHR5 272 
protein compared with wild type CFHR5 was measured. The mutant CFHR5 protein bound 273 
less PTX3 than the wild type protein, whereas the binding of fluid-phase C3b was comparable 274 
to both proteins in the assay (Fig. 3C). 275 
The interaction was confirmed using serum as a source of CFHR5 (Fig. 3D). Normal 276 
human serum and a patient serum containing both wild-type CFHR5 and the mutCFHR5 were 277 
incubated in wells coated with PTX3 and the related short pentraxin CRP. The bound proteins 278 
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were analyzed after elution and SDS-PAGE by Western blotting using polyclonal CFHR5 279 
antibody. Whereas the amount of the mutCFHR5 was clearly higher in the patient serum 280 
compared with the normal CFHR5 (Fig. 3D, lane 8), a weaker mutCFHR5 band was observed 281 
among both the PTX3- and CRP-bound proteins, confirming the results obtained with 282 
recombinant mutCFHR5. 283 
 284 
Effect of the ligands C3b and C1q on the CFHR5-PTX3 interaction 285 
The main known CFHR5 ligand is the complement fragment C3b. Therefore, we studied if 286 
C3b influences the PTX3 binding capacity of CFHR5. To this end, CFHR5 immobilized in 287 
microplate wells was preincubated with increasing concentrations of C3b. Then PTX3 was 288 
added and PTX3 binding was measured. C3b showed dose-dependent binding to CFHR5 and 289 
it did not influence the binding of PTX3 (5 µg/ml) to CFHR5 at concentrations up to 50 µg/ml 290 
(data not shown). 291 
 C1q binding to PTX3 is thought to initiate classical complement pathway activation 292 
(35). We investigated whether CFHR5 can interfere with the binding of C1q to PTX3. To this 293 
end, wells coated with PTX3 were preincubated with increasing amounts of CFHR5 and C1q 294 
binding was measured. CFHR5 could partly inhibit C1q binding to PTX3 (up to ~50% under 295 
the tested experimental conditions), whereas FH had no inhibitory effect on C1q binding to 296 
PTX3 (Fig. 4A). In a reverse setting, we analyzed if CFHR5-bound PTX3 can interact with 297 
C1q. C1q showed binding to CFHR5 which was strongly enhanced by PTX3 bound to 298 
CFHR5 (Fig. 4B). Thus, C1q can bind to CFHR5-bound PTX3. 299 
 300 
CFHR5 competes with FH for binding to PTX3 301 
The binding of FH to PTX3 is thought to down-regulate PTX3-induced complement 302 
activation (26, 27). Therefore, we assessed the ability of CFHR5 to interfere with the binding 303 
of the complement inhibitor FH to PTX3. CFHR5 strongly and dose-dependently inhibited 304 
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FH binding to PTX3, whereas the control protein human serum albumin had no effect on this 305 
interaction (Fig. 5A). Accordingly, CFHR5 inhibited the cofactor activity of PTX3-bound FH 306 
by strongly reducing FH binding to PTX3. When bound to PTX3, FH acted as a cofactor for 307 
the factor I-mediated cleavage and inactivation of C3b (Fig. 5B, lane 2), which was strongly 308 
reduced by CFHR5 added in 1:1 molar ratio to FH (300 nM each) (Fig. 5B, lane 3), while 309 
CFHR5 itself showed no cofactor activity (Fig. 5B, lane 4). 310 
 311 
CFHR5 binds to denatured, monomeric CRP and inhibits factor H binding and cofactor 312 
activity 313 
CRP shares a pentraxin domain homologous to that of PTX3. CFHR5 was shown to interact 314 
with CRP, but the CRP form which binds to CFHR5 and the functional consequence of this 315 
interaction were not investigated (4). We therefore set out to characterize the CFHR5-CRP 316 
interaction in more detail. CFHR5 did not bind the native, pentameric form (pCRP) in ELISA 317 
under our experimental conditions (Fig. 6A), but it readily interacted with the denatured, 318 
monomeric CRP (mCRP) (Fig. 6B). The control proteins used in these experiments CFHR4A 319 
and FH bound pCRP and mCRP, respectively, as expected (16). CFHR5 also bound to mCRP 320 
in the reverse setting, when mCRP was generated by immobilization of pCRP on the ELISA 321 
plates (Fig. 6C). 322 
Similar to PTX3, the binding of FH to mCRP was dose-dependently inhibited by 323 
CFHR5 (Fig. 6D). When bound to mCRP, FH displayed cofactor activity for the factor I-324 
mediated cleavage and inactivation of C3b (lane 2), which was inhibited by CFHR5 (lane 3) 325 
(Fig. 6E). CFHR5 itself showed no cofactor activity under these conditions (Fig. 6E, lane 4). 326 
 327 
CFHR5 binds to ECM, competes with FH, and recruits PTX3 328 
Previously, we showed that FH, FHL-1 and CFHR1 bind to ECM (27). Therefore, we 329 
analyzed the interaction of CFHR5 with the model ECM MaxGel. The binding of native 330 
15 
 
CFHR5 to MaxGel from serum could be detected by Western blot (Fig. 7A). Recombinant 331 
CFHR5 exhibited a strong, dose-dependent binding to MaxGel (Fig. 7B). Similarly to the 332 
case of pentraxins (Figs. 5 and 6), CFHR5 inhibited the surface-associated cofactor activity 333 
of FH by competing with its binding to MaxGel (Figs. 7C and 7D). In addition, CFHR5, but 334 
not FH, FHL-1 and CFHR1, strongly enhanced binding of PTX3 to both MaxGel and 335 
HUVEC-derived ECM (Fig. 7E). PTX3 had only minor effect on CFHR5 binding to ECM 336 
(not shown). 337 
 338 
CFHR5 competes with FH in serum 339 
To confirm that the observed competition between CFHR5 and FH occurs also in serum, 340 
wells were coated with PTX3, CRP and MaxGel and incubated with heat-inactivated serum, 341 
which was used to exclude FH binding through deposited C3 fragments. CFHR5 when added 342 
to heat-inactivated serum significantly reduced the amount of bound FH on PTX3, CRP and 343 
MaxGel (Fig. 8A). As a negative control, recombinant CFHR4A was used, which does not 344 
bind well to PTX3 (Fig. 2A), immobilized CRP (Fig. 6) (16) and MaxGel (27). In line with 345 
this, CFHR4A did not inhibit FH binding to any of these ligands (Fig. 8A). 346 
 In addition, C3 fragment deposition on PTX3, CRP and MaxGel was measured in 347 
complement active normal serum when CFHR5 was added to increase its concentration. In all 348 
cases, addition of CFHR5 but not CFHR4A caused increased C3 deposition, indicating 349 
competitive inhibition of FH activity by CFHR5 on these ligands (Fig. 8B). 350 
 351 
The C3bBb alternative pathway C3 convertase assembles on CFHR5  352 
We have previously shown that CFHR4 can activate complement by binding C3b and 353 
allowing formation of an active C3bBb alternative pathway C3 convertase (34). We analyzed 354 
whether such a C3 convertase can also be formed on CFHR5. To this end, immobilized 355 
CFHR5 was incubated with C3b, followed by the addition of purified FB, factor D and FP. 356 
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Convertase formation was detected by measuring the Bb fragment. Similar to CFHR4A, 357 
CFHR5 supported C3bBb formation, but the amount of C3 convertase was less on CFHR5 358 
compared with CFHR4A (Fig. 9A). The CFHR5-bound convertase was functional as shown 359 
by the generation of C3a after the addition of purified C3 to the convertase (Fig. 9B). We 360 
detected no binding of purified FB alone to CFHR5. We observed weak binding of purified 361 
FP to CFHR5, which could be an artefact due to the known in vitro formation of non-362 
physiological FP oligomers (Supplemental Fig. 1). 363 
Incubation of CFHR5 with 10% normal human serum supplemented with 5 mM Mg2+-364 
EGTA confirmed the generation of the alternative pathway C3 convertase as measured by 365 
deposition of C3, FB and FP (Figs. 10A-C). In serum supplemented with 5 mM EDTA, no 366 
complement activation and convertase formation was detected, as expected. The residual C3 367 
signal on CFHR4A is due to direct binding of C3 fragment(s) (Fig. 10A). 368 
369 
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Discussion 370 
 371 
The function of the factor H-related proteins is a controversial issue. Most studies reported 372 
lack of FH-like complement inhibiting activity for the CFHR proteins at physiological 373 
concentrations (11, 12, 34, 36), as expected from the domain composition of these proteins. 374 
However, weak cofactor activity for CFHR3, CFHR4 and CFHR5 (4, 37), and also strong 375 
cofactor activity for CFHR3 were reported (38). Complement regulation by other 376 
mechanisms, such as inhibition of the terminal complement pathway, were reported for 377 
CFHR1 and CFHR2 (39, 40), but others could not detect this activity (11, 41). In addition, 378 
enhancement of complement activation by CFHR4 via binding of C3b and CRP was 379 
described (32, 34). 380 
Despite the suggested complement inhibiting function for the CFHRs, microbes that 381 
bound CFHR1, CFHR2 and CFHR5 were not protected by these proteins from complement 382 
attack (42, 43). Increased expression of CFHRs under infectious conditions (44) and the 383 
described competition of CFHR1 with FH for certain bacterial ligands (45, 46) and for the 384 
major opsonin C3b (11) indicate that CFHRs may interfere with the regulatory activity of FH. 385 
Cumulatively, these data suggest that instead of inhibition of complement activation, the 386 
CFHRs rather cause enhanced activation. This could be advantageous to the human host 387 
during infections as it may help the opsonophagocytic removal of microbes, but also that of 388 
cellular debris under non-infectious conditions. Depending on the local concentration, 389 
oligomeric state, polymorphic and mutant variants, and binding strength of FH, CFHRs and 390 
their ligands, the delicate balance between complement activation/deregulation and inhibition 391 
could be shifted in favour of activation, resulting in pathologic complement activation. 392 
While currently there is no convincing evidence for physiologically relevant 393 
complement inhibiting roles of the CFHR proteins, their association with complement-394 
mediated diseases is supported by genetic studies (47). Importantly, three recent reports 395 
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showed that CFHR1, CFHR2 and CFHR5 deregulate complement by competing with FH for 396 
binding to C3b, thus they may rather enhance complement activation in human renal diseases 397 
(11-13). Our current study supports a function of CFHR5 as competitive inhibitor of FH and 398 
as enhancer of complement activation. We further investigated the role of CFHR5 in 399 
complement activation and in modulating the activity of FH, which could be particularly 400 
relevant during acute phase response (with increase in pentraxin concentrations) and 401 
endothelial injury. 402 
We identified novel CFHR5 ligands, such as PTX3, modified CRP and ECM, which 403 
are likely relevant in disease-associated roles of CFHR5. CFHR5 was implicated in particular 404 
in various kidney pathologies based on genetic and protein-level studies (6-8, 10, 11, 48). Our 405 
data suggest that not only binding of C3b or C3b fragments (such as iC3b) by CFHR5 could 406 
be important in the context of diseases, but likely also interactions with molecules, such as 407 
pentraxins that are upregulated during inflammation and renal endothelial damage, and with 408 
host surfaces such as the ECM. This is supported by recent proteomics studies, which 409 
identified both CFHR5 and PTX3 as glomerular ECM-associated proteins (49, 50). 410 
PTX3 is produced locally at the site of inflammation. Elevated PTX3 levels were 411 
described in various infectious and inflammatory diseases, including chronic kidney disease 412 
(23, 51, 52). Both protective and detrimental effects of PTX3 have been described, such as in 413 
post-ischemic renal injury (23, 53, 54). Systemic PTX3 concentration of up to ~1.5 µg/ml was 414 
reported, indicating that locally at inflammatory sites it can reach much higher concentrations, 415 
similar to those used in this study, suggesting that the studied PTX3-CFHR5 interaction has 416 
physiological relevance. 417 
A previous study described cofactor activity for CFHR5, but rather high 418 
concentrations of the protein were required for this function (4). In our current study, we 419 
found no cofactor activity of CFHR5 at the studied, physiologically relevant concentrations 420 
(Figs. 5-7). On the other hand, physiological amounts of CFHR5 significantly competed with 421 
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FH in binding to the pentraxins PTX3 and CRP, as well as to ECM. Importantly, this 422 
competition could be detected in serum and caused enhanced complement activation (Fig. 8). 423 
This represents an indirect means by which CFHR5 deregulates complement, namely, not via 424 
direct competition with FH for C3b, but by interfering with FH binding to its other 425 
physiological ligands. These data suggest that depending on the FH-binding surfaces and 426 
ligands, as well as on local FH and CFHR5 concentrations, CFHR5 can fine-tune local 427 
complement regulation by competing with FH. 428 
The binding of PTX3 to CFHR5 is the strongest among the tested FH family proteins; 429 
this explains the strong inhibitory effect of CFHR5 on FH binding to PTX3 (Figs. 1, 2 and 5). 430 
The PTX3-CFHR5 interaction is strongly reduced in Ca2+-free buffer (Fig. 2), similar to the 431 
PTX3 binding to FH, FHL-1 and CFHR1, reported previously (26, 27). 432 
Our data show that at reduced pH, which might occur at sites of inflammation, the 433 
binding of PTX3 to CFHR5 is reduced. We have previously showed that at lower pH the 434 
binding of PTX3 to C1q and CFHR1 is unchanged but the binding of PTX3 to the 435 
complement inhibitors FH, FHL-1 and C4b-binding protein is increased (27). Combined, 436 
these data suggest that under such conditions complement inhibition is preferred, because the 437 
binding of the complement inhibitors increases and that of the deregulator CFHR5 decreases. 438 
 The PTX3 binding site in CFHR5 appears not to be homologous to the two identified 439 
PTX3 binding sites in FH, i.e. FH domains CCP7 and CCP19-20. CCP1-2 of CFHR5 are the 440 
dimerization domains and very different structurally and functionally from CCP6-7 of FH. 441 
CCP2 of CFHR5 is very similar to CCP2 of CFHR1 (~85% amino acid sequence identity); 442 
however, we showed previously that PTX3 binds to CFHR1 via the C-terminus of CFHR1 443 
(27). We tested the C-terminal domains of all of the five human CFHR proteins, and only 444 
CCP4-5 of CFHR1 bound PTX3 under our experimental conditions. The CCPs 8-9 domains 445 
of CFHR5 did not bind PTX3 (Fig. 3). In addition, these domains were shown to bind C3b, 446 
and C3b did not influence PTX3 binding by CFHR5 in our experiments (not shown). 447 
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Moreover, the binding site for the related pentraxin CRP was localized to CCPs 3-7 of 448 
CFHR5 (4). Thus it is likely, but needs to be tested in the future, that the PTX3-binding site 449 
also resides within these middle domains of CFHR5. In addition, the tested disease-associated 450 
mutant CFHR5 protein, in which the two N-terminal domains are duplicated, showed reduced 451 
PTX3-binding capacity in comparison with the wild-type protein (Fig. 3). This could be 452 
caused by the restricted availability of PTX3-binding sites in the mutant which has an 453 
increased tendency to form oligomers (11). 454 
 The known PTX3 ligand C1q could partially inhibit PTX3 binding to CFHR5, but not 455 
to FH, indicating partially overlapping binding sites or conformational changes of PTX3 when 456 
bound to C1q. However, CFHR5-bound PTX3 could still strongly bind C1q (Fig. 4). We 457 
observed C1q binding to CFHR5 alone, which was strongly and significantly enhanced by 458 
PTX3. 459 
 Interaction of CFHR5 with CRP was first described by McRae et al., but the type of 460 
CRP which binds CFHR5 was not studied (4). FH binds preferentially to the modified, 461 
monomeric form of CRP via domains CCP7, CCPs 8-11 and CCPs 19-20 (15-17), and at 462 
acute phase CRP concentrations it was reported to interact also with the native pentameric 463 
form of CRP (18). By contrast, CFHR4 binds primarily to the native pCRP (16, 32). In our 464 
assays, CFHR5 bound strongly to mCRP, whereas the binding to pCRP was minor (Fig. 6). 465 
 CFHR5 also strongly and dose-dependently bound to MaxGel, in contrast to the 466 
relatively weak binding of FH (27). Accordingly, CFHR5 efficiently inhibited the binding and 467 
cofactor activity of FH on this ECM (Fig. 7). CFHR5, alone among the investigated FH 468 
family proteins, recruited PTX3 to the ECM. These results are in line with recent proteomics 469 
data demonstrating the association of both CFHR5 and PTX3 with glomerular EC-derived 470 
ECM (49, 50), and suggest that CFHR5 enhances local complement activation via these 471 
interactions. 472 
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 We also studied the direct role of CFHR5 in complement activation. In our recent 473 
study on CFHR4, we showed that C3b-binding to CFHR4 can result in the assembly of the 474 
alternative pathway C3 convertase and activation of C3 (34). In our current study, we found 475 
that CFHR5 can similarly promote C3 convertase formation and alternative pathway 476 
activation, albeit the effect was weaker compared to CFHR4 (Figs. 9 and 10). This activity 477 
stands in contrast to the complement alternative pathway inhibitory role of FH. 478 
During kidney endothelial injury, host ligands that are newly exposed (ECM) or the 479 
concentration of which is increased (pentraxins), may result in the increased binding of 480 
CFHR5 to the site of injury. The oligomeric state of CFHR5 and CRP can further fine-tune 481 
these interactions, but this needs to be characterized further. 482 
 In summary, we show that in addition to competing for C3b binding with FH as 483 
reported recently, CFHR5 may promote complement activation and complement-mediated 484 
damage/inflammation through three mechanisms: (1) by preventing the binding of the 485 
complement inhibitor FH to PTX3, CRP and ECM, (2) by allowing increased binding of the 486 
complement activation initiator molecule C1q, and (3) by supporting the assembly of the 487 
alternative pathway C3 convertase C3bBb. These functions may explain in part the disease-488 
associated role of CFHR5. 489 
490 
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Figure legends 716 
Fig. 1. CFHR5 interacts with PTX3. 717 
(A) Schematic drawing of FH, CFHR5 and CFHR4A. FH is built up of 20 CCP domains, of 718 
which CCPs 1-4 mediate complement regulatory activity and CCPs 19-20 mediate surface 719 
recognition by FH. The CCP domains of CFHR5 and CFHR4A, which was used as a control 720 
protein in several experiments, are shown aligned with the corresponding most related FH 721 
domains. The numbers above the domains indicate the percentage of amino acid sequence 722 
identity between the homologous domains. The mutant CFHR5 protein detected in CFHR5 723 
nephropathy and containing a duplication of CCPs 1-2 is also shown. CFHR4B consists of 724 
CCPs 1 and 6-9 of CFHR4A (not shown). 725 
(B) Microplate wells were coated with gelatin or PTX3, then incubated with 25% normal 726 
human plasma (NHP). After washing, bound proteins were removed by adding SDS-sample 727 
buffer and subjected to 10% SDS-PAGE and Western blotting using monoclonal anti-CFHR5. 728 
The blot is representative of three experiments. 729 
(C) Comparison of binding of CFHR5 and FH to PTX3. Immobilized PTX3 and gelatin, used 730 
as negative control protein, were incubated with the indicated concentrations of purified FH 731 
or recombinant CFHR5. Binding of both proteins was detected by a FH antibody. Data are 732 
means ± SEM derived from four experiments. Both FH and CFHR5 bound to PTX3 733 
significantly stronger than to gelatin (p < 0.001, two-way ANOVA). 734 
(D) Addition of increasing amounts of PTX3 results in a saturable binding to immobilized 735 
CFHR5. Specific binding was measured using a standard curve of PTX3. Data are mean ± 736 
SEM from eight experiments. 737 
 738 
Fig. 2. Comparison of the binding of PTX3 with CFHR proteins, and dependence of the 739 
PTX3-CFHR5 interaction on calcium concentration and pH. 740 
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(A) Binding of PTX3 to recombinant CFHR5 was compared to that of CFHR1, CFHR4A and 741 
FH by ELISA. The FH family proteins and bovine serum albumin (BSA), used as negative 742 
control, were immobilized in equimolar concentrations (200 nM) in microplate wells, then 5 743 
µg/ml recombinant PTX3 was added for 1 h at 37°C. PTX3 binding was determined using a 744 
polyclonal anti-PTX3 antibody. The values were normalized for FH binding (100%) and show 745 
means + SD derived from three independent experiments. ** p < 0.01 and *** p < 0.001, one-746 
way ANOVA. 747 
(B) The binding of PTX3 to immobilized FH and CFHR5 was compared in DPBS (pH 7.4) 748 
with (black bars) and without (white bars) 1 mM Ca2+. The data are normalized to binding in 749 
the presence of Ca2+ (100%), and represent means + SD from four experiments. *** p < 750 
0.001, one-way ANOVA. 751 
(C) The binding of PTX3 to CFHR5 was compared in TBS with pH 7.4, 6.5 and 5.5. The data 752 
shown are normalized to values obtained with TBS pH 7.4 (100%) and represent means + SD 753 
from five experiments. * p < 0.05, one-way ANOVA. 754 
 755 
Fig. 3. Characterization of the PTX3-CFHR5 interaction. 756 
(A) Gelatin, full-length PTX3 and the N- and C-terminal PTX3 fragments were immobilized 757 
in microplate wells (5 µg/ml). Binding of FH (40 µg/ml), FH8-14 (10 µg/ml) and CFHR5 (10 758 
µg/ml) was measured using polyclonal anti-FH antibody. Data are mean absorbance values + 759 
SD derived from four independent experiments. ** p < 0.01 and *** p < 0.001, one-way 760 
ANOVA. 761 
(B) Binding of PTX3 to the C-terminal CFHR domains that are the homologues of the PTX3-762 
binding CCP19-20 of FH was measured by ELISA. CCP4-5 of CFHR1, CCP3-4 of CFHR2, 763 
CCP4-5 of CFHR3, CCP8-9 of CFHR4A, CCP8-9 of CFHR5, CCP19-20 of FH, as well as 764 
the full-length FH, CFHR1, CFHR4B, CFHR5 and HSA proteins as controls, were 765 
immobilized at 5 µg/ml concentration in microplate wells. Recombinant PTX3 at 10 µg/ml 766 
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was added and its binding was detected as described for Fig. 2. Data are mean absorbance 767 
values + SD derived from three independent experiments. * p < 0.05 and *** p < 0.001, one-768 
way ANOVA. 769 
(C) Binding of PTX3 to the CFHR5 mutant with duplicated CCP1-2 (mutCFHR5) was 770 
measured by immobilizing mutCFHR5, and as controls, CFHR5 and gelatin at 10 µg/ml in 771 
microplate wells. Binding of 10 µg/ml PTX3, 10 µg/ml C3b and a CFHR5-specific polyclonal 772 
antibody was measured by ELISA as described in Materials and methods. The data are means 773 
+ SD derived from four independent experiments. * p < 0.05, one-way ANOVA. 774 
(D) Wells coated with PTX3 (lanes 1-3) and CRP (lanes 4-6) were incubated with 50% 775 
normal human serum (NHS) (lanes 2 and 5) and a patient serum containing both wild-type 776 
CFHR5 and the mutCFHR5 (lanes 3 and 6). The bound proteins were analyzed after elution 777 
and 10% SDS-PAGE by Western blotting using polyclonal CFHR5 antibody. Reactivity of 778 
the polyclonal antibody with NHS (1 µl, lane 7) and patient serum (1 µl, lane 8) is shown as a 779 
control. The blot is representative of two experiments. 780 
 781 
Fig. 4. C1q binding to PTX3 in the presence of CFHR5. 782 
(A) Binding of C1q to PTX3 was determined in the presence of increasing concentrations of 783 
CFHR5 and FH in ELISA. C1q binding was detected using C1q antibody.  The normalized 784 
values are means ± SD derived from four independent experiments. * p < 0.05 and *** p < 785 
0.001, two-way ANOVA. 786 
(B) C1q binds to CFHR5-bound PTX3. Microplate wells were coated with 5 µg/ml 787 
recombinant CFHR5 and, as control, with gelatin, and then sequentially incubated with 5 788 
µg/ml PTX3 and 25 µg/ml or 50 µg/ml C1q, as indicated. C1q binding was measured using 789 
C1q antibody. The data are means + SD derived from four independent experiments. ** p < 790 
0.01 and *** p < 0.001, one-way ANOVA. 791 
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 792 
Fig. 5. CFHR5 competes with FH binding and activity on PTX3. 793 
(A) The binding of 50 µg/ml (~300 nM) FH to PTX3 was measured in the presence of 794 
increasing concentrations of CFHR5 (up to 20 µg/ml, corresponding to ~300 nM CFHR5), 795 
using a FH-specific monoclonal antibody for detection. Human serum albumin (HSA) was 796 
used as control protein. The normalized values are means ± SD derived from four independent 797 
experiments. The binding of FH was significantly different in the presence of 20 µg/ml 798 
CFHR5 than in the presence of 20 µg/ml HSA (p = 0.0005, unpaired t-test). 799 
 (B) The cofactor activity of FH bound to PTX3 for the cleavage of C3b in the presence and 800 
absence of CFHR5 was measured by Western blot as described in Materials and methods. 801 
Microplate wells were coated with 10 µg/ml PTX3 and incubated with 50 µg/ml FH with or 802 
without 20 µg/ml CFHR5, as indicated below the blot, then C3b and factor I (FI) were added 803 
to each well. The molecular weight marker is indicated in the left, and the C3b chains and the 804 
C3b α’-chain cleavage fragments are indicated in the right. The blot was developed using 805 
HRP-conjugated C3-specific antibody that recognizes C3b and its fragments but not C3d. The 806 
blot is representative of three independent experiments. 807 
 808 
Fig. 6. Interaction of CFHR5 with CRP. 809 
(A) FH, CFHR4A and CFHR5 were immobilized in microplate wells at 5  µg/ml. After 810 
blocking, binding of 50 µg/ml pCRP was measured in TBS containing 2 mM CaCl2 and 1 811 
mM MgCl2 using a polyclonal CRP-specific antibody. Data are mean absorbance values + SD 812 
from three experiments. ***, p < 0.001, one-way ANOVA. 813 
(B) In parallel experiments, binding of 25 µg/ml mCRP, generated from pCRP by 814 
urea/chelation treatment, was measured in DPBS without Ca2+ using the same polyclonal anti-815 
CRP as in (A). Data are mean absorbance values + SD from three experiments. ***, p < 816 
0.001, one-way ANOVA. 817 
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(C) To measure CFHR5 binding to surface-bound CRP, 5 µg/ml CRP was immobilized in 818 
microplate wells, which results in the generation of mCRP. Equimolar amounts (300 nM) of 819 
CFHR5 and FH were added and their binding was detected using FH antibody. Data are mean 820 
absorbance values + SD from four experiments. ***, p < 0.001, one-way ANOVA. 821 
(D) The binding of 50 µg/ml (~300 nM) FH to CRP, immobilized in microplate wells, was 822 
measured by ELISA in the presence of increasing concentrations of CFHR5 (up to 20 µg/ml, 823 
corresponding to ~300 nM CFHR5), using a FH-specific monoclonal antibody for detection. 824 
Human serum albumin (HSA) was used as control protein. The normalized values are means 825 
± SD derived from three independent experiments. The binding of FH was significantly 826 
different in the presence of 20 µg/ml CFHR5 than in the presence of 20 µg/ml HSA (p < 827 
0.0001, unpaired t-test). 828 
 (E) The cofactor activity of FH bound to CRP for the cleavage of C3b in the presence and 829 
absence of CFHR5 was measured by Western blot. Microplate wells were coated with 10 830 
µg/ml CRP and incubated with 50 µg/ml FH with or without 20 µg/ml CFHR5, as indicated 831 
below the blot, then C3b and factor I (FI) were added to each well. The blot was developed as 832 
described for Fig. 5., and is representative of three independent experiments. The molecular 833 
weight marker is indicated in the left, and the C3b chains and the C3b α’-chain cleavage 834 
fragments are indicated in the right. 835 
 836 
Fig. 7. Interaction of CFHR5 with the extracellular matrix. 837 
(A) Microplate wells were coated with MaxGel or HSA, and incubated with normal human 838 
serum. After washing, bound proteins were removed by adding SDS-sample buffer and 839 
subjected to 10% SDS-PAGE and Western blotting using polyclonal anti-CFHR5. The blot is 840 
representative of three experiments. 841 
(B) Dose-dependent binding of recombinant CFHR5, added in the indicated concentrations, to 842 
MaxGel and gelatin (both immobilized at 20 µg/ml) was measured by ELISA using 843 
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polyclonal antibody to human CFHR5. The data are means ± SD of absorbance values derived 844 
from four independent experiments. 845 
(C) The binding of 50 µg/ml (~300 nM) FH to MaxGel was measured by ELISA in the 846 
presence of increasing concentrations of CFHR5 (up to 20 µg/ml, corresponding to ~300 nM 847 
CFHR5), using a FH-specific monoclonal antibody for detection. Human serum albumin 848 
(HSA) was used as control protein. The normalized values are means ± SD derived from three 849 
independent experiments. The binding of FH was significantly different in the presence of 20 850 
µg/ml CFHR5 than in the presence of 20 µg/ml HSA (p = 0.0027, unpaired t-test). 851 
 (D) The cofactor activity of FH bound to MaxGel for the cleavage of C3b in the presence and 852 
absence of CFHR5 was measured by Western blot. Microplate wells were coated with 853 
MaxGel (diluted 1:30) and incubated with 50 µg/ml FH with or without 20 µg/ml CFHR5, as 854 
indicated below the blot, then C3b and factor I (FI) were added to each well. The blot was 855 
developed as described for Fig. 5., and is representative of three independent experiments. 856 
The molecular weight marker is indicated in the left, and the C3b chains and the C3b α’-chain 857 
cleavage fragments are indicated in the right. 858 
(E) Binding of 5 µg/ml PTX3 to MaxGel (white bars) and HUVEC-derived ECM (black bars) 859 
preincubated with the indicated FH-family proteins at 20 µg/ml (recombinant CFHR1 and 860 
CFHR5) or 100 µg/ml (recombinant FHL-1 and purified FH) concentration was measured by 861 
ELISA as described for Fig. 2. The normalized values are means + SD derived from four 862 
independent experiments. **, p < 0.01 and ***, p < 0.001, one-way ANOVA. 863 
 864 
Fig. 8. CFHR5 competes with FH in serum for binding to PTX3, CRP and MaxGel and 865 
causes enhanced C3 fragment deposition. 866 
(A) Wells were coated with 10 µg/ml PTX3, 10 µg/ml CRP and MaxGel diluted 1:30 in 867 
DPBS. After blocking, the wells were incubated for 30 minutes at 37°C with 25% heat 868 
inactivated human serum with or without 0.5 µM CFHR5 and CFHR4A. FH binding was 869 
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detected with mAb A254 and the corresponding secondary antibody. The normalized values 870 
are means + SD derived from three independent experiments. ***, p < 0.001, one-way 871 
ANOVA. 872 
(B) Nunc microplate wells were coated with 10 µg/ml PTX3, 10 µg/ml CRP and MaxGel 873 
diluted 1:30 in DPBS. After blocking, 12.5% normal human serum (for PTX3 and CRP) and 874 
25% normal human serum (for ECM) were added for 30 minutes at 37°C, with or without 20 875 
µg/ml CFHR5 or CFHR4A. Complement activation was detected by measuring C3 fragment 876 
deposition using HRP-conjugated goat anti-human C3. Data represent mean absorbance 877 
values + SD from three independent experiments. **, p < 0.01 and ***, p < 0.001, one-way 878 
ANOVA. 879 
 880 
Fig. 9. Assembly of the alternative pathway C3 convertase on CFHR5. 881 
(A) Assembly of the C3bBb convertase on CFHR5. Recombinant CFHR4A, CFHR5 and, as 882 
negative control, HSA were immobilized in microplate wells, followed by incubation with 10 883 
µg/ml C3b. The alternative pathway C3 convertase was built up by adding purified FB, factor 884 
D and FP for 30 min at 37°C. The convertase was detected with polyclonal anti-FB antibody.  885 
The data are mean absorbance values + SD derived from five independent experiments. **, p 886 
< 0.01 and ***, p < 0.001, one-way ANOVA. 887 
(B) Activity of the CFHR5-bound convertase was measured by adding 10 µg/ml C3 to the 888 
wells for 1 h at 37°C. C3a generation was measured by Quidel’s C3a ELISA kit. Data are 889 
mean absorbance values + SD from three experiments. ***, p < 0.001, one-way ANOVA. 890 
 891 
Fig. 10. Complement activation by CFHR5. 892 
CFHR5 was immobilized on microplate wells and incubated with 10% normal human serum 893 
in 5 mM Mg2+-EGTA buffer to allow only alternative pathway activation or with 10% serum 894 
containing 5 mM EDTA to inhibit complement activation. Deposition of (A) C3b, (B) factor 895 
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B (FB) and (C) properdin (FP) was detected using the corresponding antibodies.  Immobilized 896 
CFHR4A was used as positive control and factor H and human serum albumin (HSA) were 897 
used as negative controls. The data are means + SD derived from three independent 898 
experiments. **, p < 0.01 and ***, p < 0.001, one-way ANOVA. 899 







Csincsi et al. 
Supplemental Figure 1 
 
 
Figure S1. Binding of purified C3b, factor B (FB) and properdin (FP) to CFHR5. 
Dose-dependent binding of C3b (A), FB (B) and FP (C), added in the indicated 
concentrations, to CFHR5 and HSA, both immobilized at 5 µg/ml, was measured by ELISA 
using the corresponding antibodies. Data are means ± SD from at least three independent 
experiments. *, p < 0.05 and ***, p < 0.001 (two-way ANOVA).   
 
